Colombia Antacids Market Overview, 2031

Key Insights

• According to the research report, "Colombia Antacids Market Outlook, 2031," published by Bonafide Research, the Colombia Antacids Market is expected to reach a market size of more than 72.3 Million by 2031.
• The baseline demand for antacids in Colombia remains high due to dietary patterns, rapid urbanization, and high self-medication rates across major metropolitan centers (such as Bogotá, Medellín, and Cali). Latin American clinical studies highlight that gastroesophageal reflux disease (GERD) symptoms affect between 11.9% and 19.6% of the adult population in South America, with Colombia tracking near the upper boundary in urban centers due to high intake of fried foods (arepas, fritangas), heavy coffee consumption, and late dining.
• Colombian consumers strongly favor immediate physical relief over delayed systemic action when treating acute acidity episodes. Product innovation in the Colombian retail market focuses heavily on dual-action sodium alginate suspensions paired with antacid salts (such as Gaviscon). These formulations create a protective physical raft over stomach contents while buffering acid to prevent esophageal reflux. While traditional chewable tablets hold strong market presence for portability, liquid suspensions and single-dose effervescent powders (such as Sal de Frutas Lúa and Alka-Seltzer) drive high impulse sales volume in drugstores and supermarket checkouts.
• Colombia's National Food and Drug Surveillance Institute (INVIMA) maintains clear OTC regulatory pathways, facilitating wide retail distribution of antacids beyond hospital pharmacies. Colombia features an extensive retail network of over 25,000 community pharmacies (droguerías) and specialized chain drugstores (such as Droguerías La Rebaja, Farmatodo, and Cruz Verde).

Market Outlook

• To match the mobility of urban professionals, manufacturers in Colombia are expanding single-dose liquid foil sachets and waterless chewable formulations. This packaging evolution caters to impulse purchases at neighborhood drugstores and convenience stores.
• Consumer interest in clean-label and natural self-care in Colombia is driving hybrid product development. Future OTC offerings are expected to combine fast-acting chemical neutralizers with natural soothing botanicals (such as calendula, aloe vera, or chamomile extracts) for dual acid-buffering and mucosal protection.
• The regulatory framework is governed by INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) alongside professional clinical guidance from the ACG (Asociación Colombiana de Gastroenterología), while market supply is led by major domestic and multinational pharmaceutical companies including Tecnoquímicas (Sal de Frutas Lúa), Bayer (Alka-Seltzer, Rennie), Reckitt Benckiser (Gaviscon), Procaps Group, Sanofi, and Laboratorios Bussié.

Market Dynamics

Driver: Increasing prevalence of digestive ailments and demand for rapid relief
The main driver for Colombia's antacids market is the increasing prevalence of digestive problems such as heartburn, indigestion, bloating and IBS, which is supporting demand for digestive remedies. Euromonitor specifically identifies increasing digestive ailments as a key 2025 demand driver and expects steady growth in digestive remedies, led in part by antacids. Antacids benefit because they provide relatively rapid relief from heartburn and are accessible for self-treatment.
Challenge: Competition from natural remedies and alternative digestive products
A key challenge is the shift toward natural remedies and broader digestive-health solutions. Euromonitor's 2025 consumer research found that 33% of Colombians prefer natural remedies over OTC solutions for gastrointestinal discomfort such as IBS. This preference creates substitution pressure for conventional pharmaceutical digestive products, including antacids.
Trend: Pharmacy dominance alongside rapid expansion of discount retail
A significant distribution trend is the continued importance of pharmacies combined with the rapid expansion of discount retailers. Euromonitor identifies pharmacies as the leading channel for digestive remedies in Colombia, while discounters are expanding rapidly. This is important for antacids because they are relatively low-cost, frequently purchased OTC products where availability and price visibility can strongly influence purchasing. Discount retailers can broaden access among price-sensitive consumers and put additional pressure on branded manufacturers to offer competitive pack sizes and pricing.

Procurement and Industry Impact

• Colombia's diverse import base provides manufacturers with access to pharmaceutical materials from multiple international sources. However, reliance on imported pharmaceutical inputs can expose manufacturers to exchange-rate movements, international freight costs and geopolitical or manufacturing disruptions. For antacids, procurement teams should therefore compare suppliers not only on quoted API price but also on quality, lead time, regulatory documentation, minimum order quantities and supply reliability.
• Euromonitor identifies pharmacies as the leading distribution channel for digestive remedies while noting rapid expansion of discounters. At the same time, the overall digestive-remedies market is expected to achieve steady growth, with antacids among the key contributors. This channel structure increases pressure on manufacturers to deliver products with competitive unit economics, reliable replenishment and retailer-friendly packaging. Discounters in particular can encourage lower price points, making production efficiency important for maintaining margins.

Segment Analysis

Colombia Antacids Market By Drug Class
• Acid neutralizers remain closely associated with rapid, symptom-oriented relief in Colombia because they act directly on gastric acid already present in the stomach. Calcium carbonate, aluminium hydroxide, magnesium hydroxide and sodium bicarbonate are among the established antacid approaches. Colombia's national therapeutic-information platform identifies calcium carbonate as an OTC antacid, with conventional and chewable tablets available for relief of heartburn, acid indigestion and stomach discomfort.
• Proton Pump Inhibitors (PPIs) occupy a more sustained acid-control position because they suppress acid secretion rather than neutralizing acid already present. They are more relevant when reflux symptoms are recurrent or clinically significant. Colombia's 2025 GERD clinical guideline emphasizes distinguishing occasional reflux symptoms from GERD requiring structured treatment, making PPIs more closely associated with persistent disease management than with simple occasional antacid use.
• H2 antagonists provide another mechanism for reducing gastric acid secretion and can occupy an intermediate position between rapid antacid relief and longer-duration PPI treatment. Their relevance is greater for consumers requiring acid suppression but not necessarily long-term therapy. The segment competes with both familiar antacid formulations and increasingly established PPI-based treatment strategies.
• Pro-motility agents represent a specialized gastrointestinal segment because their principal purpose is to influence gastric emptying and intestinal movement rather than neutralize acid. They can become relevant when reflux symptoms coexist with post-meal fullness, delayed gastric emptying or other motility-related complaints. Their use is therefore more clinically directed than conventional Colombian OTC antacid consumption.
• Combination formulations are important because Colombian consumers may experience heartburn together with gas, bloating, indigestion or acid regurgitation. Colombia's regulatory framework explicitly recognizes antacids combined with antiflatulent ingredients, while the national therapeutic information system also identifies the use of calcium carbonate as an antacid and antiflatulent. This supports multi-symptom positioning as a way for brands to differentiate in a mature digestive-health category.

Colombia Antacids Market By Dosage Form
• Tablets and chewables are particularly suited to Colombia's self-care environment because they provide portable, standardized dosing and can be taken without measuring equipment. Calcium carbonate is officially described as available in both conventional and chewable tablet forms in Colombia. Chewables are particularly convenient for consumers experiencing symptoms after meals or while away from home.
• Liquid suspensions provide an important alternative for consumers who have difficulty swallowing tablets or prefer liquid medicines. They can accommodate aluminium- and magnesium-based combinations and permit flexible formulation. Uniform suspension, accurate dosing, flavour and clear instructions are important competitive factors, particularly because liquid products require greater consumer attention during administration.
• Powders offer a convenient non-tablet format that can be packaged in individual sachets and prepared shortly before use. They are well suited to consumers seeking portability and rapid preparation. However, preparation requirements can make them less convenient than ready-to-use liquids or chewables, while moisture protection becomes important for maintaining product quality.
• Gels and syrups provide smooth administration and can be positioned around both acid relief and reflux-barrier effects. Gel-type formulations containing alginate can create a physical barrier against reflux, giving them a differentiated mechanism compared with simple acid neutralization. Syrup-style products can also compete through flavour, viscosity and ease of swallowing.
• Gummies and other formats represent a newer consumer-oriented opportunity within Colombia's digestive-health category. Gummies offer portability and a familiar administration experience, but incorporating sufficient quantities of conventional antacid ingredients while maintaining acceptable taste and texture can be technically challenging. Effervescent and rapidly dispersible formats therefore provide alternative opportunities for convenience-focused differentiation.

Colombia Antacids Market By Indication
• Gastroesophageal Reflux Disease (GERD) is a significant indication supporting Colombia's acid-control market. Colombia's updated 2025 clinical guideline reports an estimated 11.98% prevalence of reflux symptoms, based on a population survey covering 6,842 people across Bogotá, Cali, Medellín and Barranquilla. The same research found substantial differences between cities, with Barranquilla at 16.22% and Bogotá at 10.75%.
• Heartburn is one of the strongest consumer-facing indications because the symptom is readily recognizable and often encourages direct self-treatment. The Colombian population survey reported 13.6% prevalence of heartburn, while 16.9% experienced regurgitation. These figures demonstrate that the consumer population experiencing reflux-related symptoms can be broader than the population formally diagnosed with GERD.
• Peptic ulcer represents a more medically managed indication than occasional heartburn. Antacids can provide symptomatic relief from acid-related discomfort, but they do not address underlying causes such as H. pylori infection or NSAID-associated mucosal injury. Consequently, PPIs and cause-directed therapies have a more important role in disease management, while conventional antacids remain primarily positioned around short-term symptom relief.
• Others include dyspepsia, acid indigestion, epigastric discomfort, gastritis-related symptoms, bloating and post-meal fullness. Colombia's reflux survey reported 16.67% prevalence of epigastric pain, 11.4% nausea, and 8.17% sleep disturbance caused by heartburn or regurgitation. The overlap of these symptoms creates opportunities for products positioned around broader upper-GI comfort rather than acidity alone.

Colombia Antacids Market By Distribution Channel
• Retail pharmacies remain a strategically important channel because Colombian consumers can obtain appropriately classified OTC medicines without a prescription. Colombia's official medicines platform defines OTC medicines as products consumers can purchase without a prescription for recognizable mild symptoms or conditions, while INVIMA maintains an official list of permitted OTC active ingredients, formulations and concentrations.
• Hospital pharmacies serve a more clinically supervised segment involving patients with diagnosed GERD, peptic ulcers, severe reflux and other gastrointestinal disorders. Distribution through hospitals is therefore more closely influenced by physician diagnosis, institutional treatment protocols and prescription medicine utilization than by spontaneous consumer purchases.
• Online pharmacies / E-commerce provide additional convenience for repeat purchases, allowing consumers to compare brands, dosage forms and pack sizes before ordering. The online opportunity is particularly relevant for familiar OTC products because consumers can reorder products they have previously used. However, online distribution remains dependent on Colombia's pharmaceutical authorization framework and the legal status of individual products.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Antacids Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Class
• Acid Neutralizers
• Proton Pump Inhibitors (PPIs)
• H2 Antagonists
• Pro-Motility Agents
• Combination Formulations

By Dosage Form
• Tablets & Chewables
• Liquid Suspensions
• Powders
• Gels & Syrups
• Gummies & Other

By Indication
• Gastroesophageal Reflux Disease
• Heartburn
• Peptic Ulcer
• Others

By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies / E-Commerce